Purified (azide-free) anti-beta-Amyloid, 1-42 805501 from BioLegend

Published Figures

Register or Sign In to View Figures.

Nature communications
November 30 2020

Fig 1: Cluster distribution within donors and provenance of clusters.a Distribution of cells among the different cell clusters for each donor. Each column represents a cluster, and each row represents a subject. The data are presented as the percentage of the cells in a given cluster within a given donor. Cluster 1 is the most abundant cluster in all subjects. Each cluster is color coded according to Fig. 2. b Clusters with differential proportions in the DLPFC (AD & MCI) autopsy samples versus the TNC (TLE) surgical tissue samples. Boxplots of the distribution of proportions of the 4 clusters with statistically significant differences between the two sample groups. The DLPFC (AD & MCI) group contains 14,142 cells from 14 donors (MCI1 GM - MCI4 GM, AD1 GM- AD10 GM), while the TNC (TLE) group contains 2103 cells from 3 donors (TLE1 CTX – TLE3 CTX). Significance was assessed using the (non-parametric) Mann–Whitney test, resulting in the p-values shown for each cluster. All tests were two-sided. The boxes represent the 25th percentile, median, and 75th percentile. The whiskers extend to the furthest value that is no more than 1.5 times the inter-quartile range (default parameter for R’s boxplot function). Source data for this figure are provided in the Source Data file. DLPFC dorsolateral prefrontal cortex, TNC temporal neocortex, MCI mild cognitive impairment, AD Alzheimer’s disease, TLE temporal lobe epilepsy, GM gray matter, CTX cortex.
Register or Sign In to View Figures.

Alzheimer's & dementia : the journal of the Alzheimer's Association
November 01 2022

Fig 2: APP misdistribution in the hippocampus of AD patients (A) Scheme of full-length APP showing the epitopes in the Nter, Cter and Aß domains of six antibodies against APP. The red segment represents the Aß sequence spanning through the transmembrane (TM) domain. (B) Pictures of human hippocampal sections stained by DAB against APP-Cter with C1/6.1 antibody. Cases from control, FAD and SAD groups are illustrated. The first panel on the left depicts different anatomical regions where the subsequent quantifications have been performed. In controls, APP is stained mostly in the soma of neuronal layers of the dentate gyrus granule cells (GCL), CA4 and CA3. In both FAD and SAD cases, intense extrasomatic APP stainings are observable. (C) Image magnification of the dentate gyrus as in ‘B’. In the SAD case, intense extra-somatic APP accumulations are observable in the dentate gyrus molecular layer (ML), GC and CA4 regions. (D) Histogram of the number of APP-Cter accumulations in different hippocampal regions in the control (ctrl), FAD or SAD conditions. APP accumulations are barely detected in Ctrl whereas they are abundant in AD. The number of accumulations is higher in FAD compared to SAD condition. (E) Histogram of the area of APP accumulations in different hippocampal regions. The CA regions contain larger APP accumulations than the ML. (F) Human hippocampal sections fluorescently immuno-labeled against APP-Cter with Y188 antibody and APP-Nter with JRD32. In controls, both Cter and Nter APP antibodies mostly label the soma of neurons in the GCL, CA4 and CA3. In addition, Y188 nonspecifically stained the white matter tracts (see FigS1C). In both FAD and SAD cases, intense extra-somatic APP stainings, co-labeled with the two antibodies are observable. (G) Close-up picture of an APP accumulations co-labeled with APP-Cter and Nter antibodies. (H) Scatter plot of Manders overlapping coefficients (MOC) (Method described in FigS1L-M) between APP-Cter and Nter labelings. The analysis revealed a high colocalization between the two channels suggesting the presence of full-length APP in the accumulations. (I) Scatter plot of the intensity of APP labelling in the GC soma normalized to the mean intensity in controls. The intensity is significantly reduced in the AD group (J) Graph of the mean pixel intensity of APP staining in neuronal somas in function of the area covered by APP accumulations (normalized to the hippocampus area). The linear regression of the data presents a negative slope. The Pearson correlation coefficient was -0.53 for DG (p = 0.035), -0.43 for CA3 (p = 0.046), indicative of an inverse correlation between the extent of APP accumulations and APP intensity in the neuronal soma
Register or Sign In to View Figures.

Alzheimer's & dementia : the journal of the Alzheimer's Association
November 01 2022

Fig 3: Phospho-Tau concentrate in APP accumulations (A) Pictures of a human hippocampal section labeled against APP-Cter and MAP2 and with methoxy-X04. The lower panels show a hippocampal dense-core plaque (revealed by methoxy-X04) and surrounded by APP-Cter. It corresponds to a dark area in the MAP2 channel. (B) Pictures as in (A) but with SMI312. The lower panels show a hippocampal dense-core plaque (revealed by methoxy-X04) and surrounded by APP-Cter. Some SMI312 positive neurites surrounds the plaques but do not colocalize with APP-Cter. (C) Hippocampal sections stained for APP, MBP and DAPI. APP accumulations are mostly found out of regions labelled for MBP. The close-up pictures show the absence of colocalization between MBP and APP. (D) Hippocampal sections stained for APP, BACE1 and methoxy-X04. Close-up pictures show several enlarged neurites positive for BACE1 which colocalizes with APP. (E) Hippocampal sections stained for APP, Tau and methoxy-X04. Close-up pictures show few enlarged neurites positive for Tau and negative for APP. (F) Hippocampal sections stained for APP, phosphorylated-tau (P-Tau) and methoxy-X04. Close-up pictures show several enlarged neurites positive for P-Tau which colocalizes with APP. (G) Scatter plot of the MOC between APP-Cter and the neuritic markers labeled in Fig3. The colocalization is low for MAP2, SMI312, MBP, and Tau but high for BACE1 (0.7) and P-Tau (0.53). (H) Scatter plot of the intensity of P-Tau labeling within APP accumulations. The data are normalized to the intensity outside the APP accumulations represented here by a dashed line. The analysis revealed that BACE1 and P-Tau are enriched inside the APP accumulations
Register or Sign In to View Figures.

Alzheimer's & dementia : the journal of the Alzheimer's Association
November 01 2022

Fig 4: APP accumulations surround dense-core amyloid plaques enriched in APP-Nter (A) Human hippocampal sections fluorescently immuno-labeled against APP-Cter and Aß42 with respectively Y188 and 12F4 antibodies and with methoxy-X04. In both FAD and SAD cases, intense Aß42 and methoxy-X04 labelings are observable in close proximity to APP accumulations whereas no staining is observable in control. (B) Histogram of the density of diffuse and dense core plaque in the hippocampus in the control (ctrl), FAD or SAD conditions. Moderate and similar amounts of diffuse plaques could be found in AD but also control patients. On contrary, dense core plaques were specific of the AD groups and between them, they were more abundant in FAD compared to SAD patients. (C) Close-up images of APP accumulations surrounding an amyloid plaque co-labeled with Aß42 and methoxy-X04. Aß42 and methoxy-X04 colocalize well together but not with APP-Cter. (D) Graph of a Sholl analysis of the number of APP accumulations in function of the distance from the edge of Aß42 plaques. More APP accumulations are present close to the amyloid plaques. (E) Graph of the total area covered by amyloid plaques in the hippocampus of AD cases in function of the total area of APP accumulations. The linear regression of the data presents a positive slope. The Pearson correlation coefficient was 0.79 (p = 0.011), indicative of a positive correlation between the amyloid load and the extent of APP accumulations. (F) Scatter plot of MOC between methoxy-X04 and/or APP-Cter and/or Aß42. The analysis revealed a high colocalization between methoxy-X04 and Aß42 but between methoxy-X04 and APP-Cter or between APP-Cter and Aß42 indicating that amyloid plaques and APP accumulations are located nearby but are nonoverlapping. (G) Close-up pictures of hippocampal amyloid plaques labelled with APP-Cter, Nter and methoxy-X04 revealed a remarkable abundance of APP-Nter in the core of dense core amyloid plaques surrounded by APP. (H) Scatter plot of the MOC between methoxy-X04 and APP-Nter or Cter. The analysis revealed a high colocalization between methoxy-X04 and APP-Nter but not with APP-Cter. (I) Scatter plot of the intensity of APP-Cter or Nter labelings within the core of the plaques labeled with methoxy-X04. The data are normalized to the intensity outside the plaques and accumulations represented here by a dashed line. The analysis revealed that APP-Nter is enriched in the core of the plaques whereas APP-Cter is not.
Register or Sign In to View Figures.

Alzheimer's & dementia : the journal of the Alzheimer's Association
November 01 2022

Fig 5: The number of APP accumulations inversely correlate with neuronal density (A) Sections of the somatosensory cortex of APP/PS1 immuno-labeled with NeuN and APP-Cter. Using NeuN labelling as a neuronal reporter, we counted neurons in 100 µm-side squares, used as regions of interest (ROIs). The squares were placed in different regions along the sagittal to temporal axis containing or not one or several APP accumulations. (B) Analyses of pictures as in ‘A’ revealed an inverse relationship between the area covered by APP accumulations and neuronal density within the ROIs, the larger the area covered by the APP accumulations, the fewer neurons were present. (C) Pictures of APP/PS1 brain sections immuno-labeled with NeuN and APP-Cter. ROIs of the whole hippocampal molecular layer (ML) area and of the somatosensory cortex (SSC) where numbers of neurons were counted (results in ‘D’ and ‘E’) are highlighted by dashed lines. (D, E) Analyses of pictures as in ‘C’ revealed a neuronal loss in APP/PS1 at both 5 and 9 months-old in SC and in ML. The WT littermates do not present any neuronal loss

Be the first to write a review!

Citations:

(43)

Figures:

Supplier Page

Supplier Page from
BioLegend for
Purified (azide-free) anti-beta-Amyloid, 1-42

BioLegend's Purified (azide-free) anti-beta-Amyloid, 1-42 is a Mouse monoclonal antibody. The Purified (azide-free) anti-beta-Amyloid, 1-42 Antibody was generated using APP as the antigen. It reacts with Homo Sapiens, Human, Mouse, and Rat. This antibody has been shown to work in applications such as: EIA, Immunoassay, ELISA, Immunohistochemistry, Immunohistochemistry - fixed, and Western Blot.

Description

Purified (azide-free) anti-beta-Amyloid, 1-42 [12F4]

Product Specs
ItemPurified (azide-free) anti-beta-Amyloid, 1-42
CompanyBioLegend
Price Pricing Info Supplier Page View Company Product Page
Catalog Number805501
Quantity200 µL
ApplicationsImmunohistochemistry (IHC)-P, Direct ELISA, Western Blot (WB), Immunohistochemistry (IHC)-F
Concentration0.50 mg/mL
Conjugate/TagUnconjugatedAF
FormatPhosphate-buffered solution (no preservatives or carrier proteins)
ReactivityHuman, Mouse, Rat
IsotypeIgG1, Kappa
Clone12F4
HostMouse
NCBI Full Gene Nameamyloid beta precursor protein
NCBI Gene AliasesAAA, ABETA, ABPP, AD1, APPI, CTFgamma, CVAP, PN-II, PN2, alpha-sAPP, preA4
ClonalityMonoclonal
Brand/TrademarkSIG-39142-200
Targetbeta-Amyloid 1-42

Add to Compare List

BioLegend

8999 BioLegend Way

San Diego, California 92121

United States

Phone: 1-877-246-5343 Toll-Free, USA & Canada
1-858-768-5800 International
Fax: 1-877-455-9587

Company Profile

Website: biolegend.com

(1) INPP5D regulates inflammasome activation in human microgliaNature CommunicationsNovember 29, 2023Vicky Chou, Richard V. Pearse, Aimee J. Aylward, Nancy Ashour, Mariko Taga, Gizem Terzioglu, Masashi Fujita, Seeley B. Fancher, Alina Sigalov, Courtney R. Benoit, et al.immunostained for IBA1 (1:100, Wako, 011-27991), INPP5D (1:100, abcam, ab45142) and Aβ42 (1:300, Biolegend, 805501). Alternate brain sections were immunostained for IBA1, Aβ42, and ASC (Cell Signaling Technologies,

(2) Exploring the Role of NCX1 and NCX3 in an In Vitro Model of Metabolism Impairment: Potential Neuroprotective Targets for Alzheimer’s DiseaseBiology (Basel)July 14, 2023Alessandra Preziuso, Silvia Piccirillo, Giorgia Cerqueni, Tiziano Serfilippi, Valentina Terenzi, Antonio Vinciguerra, Monia Orciani, Salvatore Amoroso, Simona Magi, Vincenzo LaricciaAntibodies Aβ1–42 peptides were detected using a mouse monoclonal IgG1 antibody (clone 12F4, Cat. 805501, Biolegend, San Diego, CA, USA, dilution 1:100 in PBS with 1% BSA). pTau protein was evaluated by using

(3) APP accumulates with presynaptic proteins around amyloid plaques: A role for presynaptic mechanisms in Alzheimer's disease?Alzheimer's & dementia : the journal of the Alzheimer's AssociationNovember 1, 2022Jordà-Siquier T, Petrel M, Kouskoff V, Smailovic U, Cordelières F, Frykman S, Müller U, Mulle C, Barthet G.buffer,Rabbit,1:500 PS1‐CTF (33B10),N. Robakis laboratory,–,Citrate buffer,Mouse,1:500 Aβ42 (12F4),BioLegend,805501,Formic acid 70%,Mouse,1:500 Aβ1‐16 (DE2),Sigma Aldrich,MAB5206,Citrate buffer,Mouse,1:500 MAP2,Sigma Aldrich

(4) A new K+channel-independent mechanism is involved in the antioxidant effect of XE-991 in an in vitro model of glucose metabolism impairment: implications for Alzheimer’s diseaseCell Death DiscoverySeptember 20, 2022Silvia Piccirillo, Alessandra Preziuso, Salvatore Amoroso, Tiziano Serfilippi, Francesco Miceli, Simona Magi, Vincenzo Laricciaantibodies Aβ1-42 protein was identified by using a mouse monoclonal IgG1 antibody (clone 12F4, Cat. 805501, Biolegend, San Diego, CA, USA, dilution 1:100 in PBS with 1% BSA). As for pTau protein, a human PHF-Tau

(5) Venular amyloid accumulation in transgenic Fischer 344 Alzheimer’s disease ratsScientific ReportsSeptember 10, 2022J. Bishay, T. L. Beckett, A. Y. Lai, M. E. Hill, D. McMahon, J. McLaurinUSA, 800701), 6E10 (Biolegend, USA, 803015), Aβ40 (Biolegend, USA, 805401), and Aβ42 (Biolegend, USA, 805501), followed by one of Alexa Fluor 488-conjugated goat anti-rabbit (1:200, Invitrogen, USA, A11008), Lectin

(6) Norovirus Intestinal Infection and Lewy Body Disease in an Older Patient with Acute Cognitive ImpairmentInternational Journal of Molecular SciencesJuly 29, 2022Manuel Moreno-Valladares, Veronica Moncho-Amor, Iraide Bernal-Simon, Eñaut Agirre-Iturrioz, María Álvarez-Satta, Ander Matheuwere used: alpha-synuclein (BioLegend, Ref.: 807701), anti-β-Amyloid, 1-42 antibody (BioLegend, Ref.: 805501, Clone: 12F4), phospho-tau (ThermoFisher, Ref.: MN1020, Clone: AT8), NeuN (Millipore, Ref.: MAB377,

(7) Alzheimer disease neuropathology in a patient previously treated with aducanumabActa NeuropathologicaJuly 1, 2022Edward D. Plowey et al.3–7; Biogen, PQ14409-126; 0.28 µg/mL; CC1 antigen retrieval for 16 min); Aβ1–42 (clone 12F4; BioLegend 805501; 1.0 µg/mL; 88% formic acid antigen retrieval for 3 min); Aβ1–4o (clone 11A50-B10; BioLegend 805401;

(8) Hypocretin/orexin influences chronic sleep disruption injury in the hippocampusFrontiers in aging neuroscienceJanuary 1, 2022Nick H, Fenik P, Zhu Y, Veasey S.temperature and/or 4°C. Primary antibodies used were: Aβ42 (C-term), AB5078P Millipore; Aβ42 (12F4), 805501 Biolegend; Glial fibrillary acidic protein, (GFAP), 13-0300 Thermo Fisher Scientific; Ionized calcium-binding

(9) Targeting MicroRNA-485-3p Blocks Alzheimer's Disease ProgressionInternational journal of molecular sciencesDecember 4, 2021Koh HS, Lee S, Lee HJ, Min JW, Iwatsubo T, Teunissen CE, Cho HJ, Ryu JH.transduction. Thereafter, the following primary antibodies were applied: rabbit anti-β-amyloid (1–42) (#805501, 1:50; Biolegend), mouse anti-cleaved tau (#AHB0061, 1:50; Invitrogen), mouse anti-phospho-tau (#MN1050,

(10) Aβ43 aggregates exhibit enhanced prion-like seeding activity in miceActa Neuropathologica CommunicationsDecember 1, 2021Alejandro Ruiz-Riquelme, Alison Mao, Marim M. Barghash, Heather H. C. Lau, Erica Stuart, Gabor G. Kovacs, K. Peter R. Nilsson, Paul E. Fraser, Gerold Schmitt-Ulms, Joel C. WattsLaboratories). Immunostaining was performed using the following antibodies: anti-Aβ42 12F4 (BioLegend #805501; 1:2,000 dilution) or anti-Aβ (N-terminus) 82E1 (IBL America #10323; 1:1000 dilution). Sections were

(11) Late-in-life neurodegeneration after chronic sleep loss in young adult miceSleepAugust 13, 2021Owen JE, Zhu Y, Fenik P, Zhan G, Bell P, Liu C, Veasey S.blocking buffer for 1–3 days at 4°C. Primary antibodies used were: Aβ42, AB5078P Millipore; Aβ42 (12F4), 805501 BioLegend; AT8 tau, (P-Ser202/Thr205), MN1040 Thermo Fisher; CD68, Ab125212 Abcam; GFAP, 13–0300 Thermo Fisher

(12) Administration of Bifidobacterium bifidum BGN4 and Bifidobacterium longum BORI Improves Cognitive and Memory Function in the Mouse Model of Alzheimer's DiseaseFrontiers in aging neuroscienceJanuary 1, 2021Kim H, Kim S, Park SJ, Park G, Shin H, Park MS, Kim J.(Millipore, MAB377), MAP2 (Invitrogen, 13-1,500), BDNF (Invitrogen, OSB00017W), β-amyloid 1–42 (Biolegend, 805501), Cleaved-caspase3 (Cell Signaling, 9661S) and appropriate fluorescent secondary antibodies (Invitrogen).

(13) Novel Multitarget Directed Tacrine Hybrids as Anti-Alzheimer's Compounds Improved Synaptic Plasticity and Cognitive Impairment in APP/PS1 Transgenic MiceACS chemical neuroscienceDecember 16, 2020Li K, Jiang Y, Li G, Liu T, Yang Z.

(14) Single cell RNA sequencing of human microglia uncovers a subset associated with Alzheimer's diseaseNature communicationsNovember 30, 2020Olah M, Menon V, Habib N, Taga MF, Ma Y, Yung CJ, Cimpean M, Khairallah A, Coronas-Samano G, Sankowski R, et al.1:100), mouse anti-human PCNA (Invitrogen; 13-3900; 1:100), and mouse anti-human beta-amyloid (Biolegend; 805501; 1:500). The secondary antibodies used were goat anti-mouse IgG (H+L) highly cross-adsorbed secondary

(15) Cognitive Decline and Modulation of Alzheimer's Disease-Related Genes After Inhibition of MicroRNA-101 in Mouse Hippocampal NeuronsMolecular neurobiologyJuly 1, 2020Barbato C, Giacovazzo G, Albiero F, Scardigli R, Scopa C, Ciotti MT, Strimpakos G, Coccurello R, Ruberti F.

(16) Identification of early pericyte loss and vascular amyloidosis in Alzheimer's disease retinaActa neuropathologicaMay 1, 2020Shi H, Koronyo Y, Rentsendorj A, Regis GC, Sheyn J, Fuchs DT, Kramerov AA, Ljubimov AV, Dumitrascu OM, Rodriguez AR, et al.Pharmaceutica,N/A,1:2000 FL CD31 pAb,Rabbit,1:50,Abcam,ab28364 Aβ42 (12F4) mAb,Mouse,1:200,Biolegend,805501 4G8 mAb,Mouse,1:200,Biolegend,800701 6E10 mAb,Mouse,1:200,Biolegend,803001 Caspase-3 pAb,Rabbit,1:500,Abcam,ab13847 Cleaved

(17) Haematopoietic stem cell gene therapy with IL ‐1Ra rescues cognitive loss in mucopolysaccharidosis IIIA EMBO Molecular MedicineMarch 6, 2020Helen Parker et al.

(18) Clinically accurate diagnosis of Alzheimer's disease via multiplexed sensing of core biomarkers in human plasmaNature communicationsJanuary 8, 2020Kim K, Kim MJ, Kim DW, Kim SY, Park S, Park CB.

(19) Beta-amyloid pathology in human brain microvessel extracts from the parietal cortex: relation with cerebral amyloid angiopathy and Alzheimer’s diseaseActa NeuropathologicaMay 1, 2019Philippe Bourassa, Cyntia Tremblay, Julie A. Schneider, David A. Bennett, Frédéric Calon,Smooth muscle cell,Rabbit,1:1000,1:100,Abcam,ab5694 Aβ40,Aβ peptide,Mouse,----------,1:100,BioLegend,805401 Aβ42,Aβ peptide,Mouse,----------,1:100,BioLegend,805501 ABCB1,BBB transporter,Rabbit,1:2000,1:100,Abcam,ab170904 APP,Aβ precursor,Mouse,1:500,----------,BioLegend,803003 BACE1,Aβ

(20) Highly sensitive quantification of Alzheimer's disease biomarkers by aptamer-assisted amplificationTheranosticsJanuary 1, 2019Chan HN, Xu D, Ho SL, He D, Wong MS, Li HW.

Be the First to Write a Review!

Nature communications

Alzheimer's & dementia : the journal of the Alzheimer's Association

Alzheimer's & dementia : the journal of the Alzheimer's Association

Alzheimer's & dementia : the journal of the Alzheimer's Association

Alzheimer's & dementia : the journal of the Alzheimer's Association

Purified (azide-free) anti-beta-Amyloid, 1-42 from BioLegend

Description

BioLegend

Citations (43)

Reviews

Purified (azide-free) anti-beta-Amyloid, 1-42 from BioLegend

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map